<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925856</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02195-52</org_study_id>
    <nct_id>NCT04925856</nct_id>
  </id_info>
  <brief_title>Immunomonitoring of Breast Cancer Patients During Systemic Treatment</brief_title>
  <acronym>IMMUNE CAPTURE</acronym>
  <official_title>Immunomonitoring of Breast Cancer Patients During Systemic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to constitute a most complete biological collection for patients treated for&#xD;
      localized or metastatic breast cancer (in different cohorts depending on the type of systemic&#xD;
      treatment received), in order to describe the basal immune response of patients treated for a&#xD;
      breast cancer according to the stage of the disease, but above all to study how the different&#xD;
      systemic treatments used in the management of breast cancer modulate this immune response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to describe, depending on the type of systemic treatment&#xD;
      received, the blood immune response before treatment and its evolution under treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">May 26, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 26, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood immune response blood immune response blood immune response</measure>
    <time_frame>24 months</time_frame>
    <description>realization of a plasma library, immunophenotyping and a PBMC bank&#xD;
realization of a plasma library, immunophenotyping and a PBMC bank&#xD;
realization of a plasma library, immunophenotyping and a PBMC bank&#xD;
realization of a plasma library, immunophenotyping and a PBMC bank&#xD;
realization of a plasma library, immunophenotyping and a PBMC bank</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 différents cohorts:&#xD;
Paclitaxel cohort (N=30)&#xD;
Epirubicine - cyclophosphamide cohort (N=30)&#xD;
Eribuline cohort (N=30)&#xD;
Palbociclib ou Abemaciclib ou Ribociclib cohort (N=60)&#xD;
Study diagram :&#xD;
Inclusion and screening visite&#xD;
Visit 1: J1C1&#xD;
Visit 2 : J8C1 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C1 to Palbociclib ou Abemaciclib ou Ribociclib cohort&#xD;
Visit 3 :J21C1&#xD;
Visit 4 : J8C3 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C3 to Palbociclib ou Abemaciclib ou Ribociclib cohort&#xD;
During these visits, we collect, before the start of treatment administration ;&#xD;
Vital signs,&#xD;
Concomitant treatments,&#xD;
Blood sample:&#xD;
1 heparinized tube (4 mL) for collection of plasma and storage&#xD;
1 heparinized tube (4 mL) for immunophenotyping,&#xD;
4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>•Blood sample:&#xD;
1 heparinized tube (4 mL) for collection of plasma and storage&#xD;
1 heparinized tube (4 mL) for immunophenotyping,&#xD;
4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman aged between 18 and 85.&#xD;
&#xD;
          2. Patient with histologically proven infiltrating breast cancer.&#xD;
&#xD;
          3. Triple negative breast cancer or RH + / HER2- (OR and RP &lt;10% and HER2 negative (0 or&#xD;
             1+ in IHC or 2+ in IHC and FISH negative)&#xD;
&#xD;
          4. Patient receiving treatment corresponding to one of these cohorts:&#xD;
&#xD;
               -  In a metastatic situation with establishment of treatment with Paclitaxel&#xD;
                  regardless of the treatment line&#xD;
&#xD;
               -  In a metastatic situation with establishment of treatment with Epirubicin -&#xD;
                  cyclophosphamide (EC) regardless of the treatment line&#xD;
&#xD;
               -  In a metastatic situation with establishment of treatment with Eribulin&#xD;
                  regardless of the line of treatment&#xD;
&#xD;
               -  In a 1st line metastatic situation with initiation of treatment with Palbociclib&#xD;
                  or Abemaciclib, or Ribociclib in combination with hormone therapy (aromatase&#xD;
                  inhibitor)&#xD;
&#xD;
          5. Patient who signed the informed consent for the study.&#xD;
&#xD;
          6. Patient fit and able to adhere to protocol for the duration of the study, including&#xD;
             visits, scheduled specimens and follow-up.&#xD;
&#xD;
          7. Patient affiliated to the social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient unable to understand, read and / or sign informed consent.&#xD;
&#xD;
          2. Presence of cerebral or meningeal metastasis&#xD;
&#xD;
          3. Current or previous use of an immunosuppressive drug in the 14 days preceding&#xD;
             inclusion (except intranasal corticosteroids, systemic corticosteroids at&#xD;
             physiological doses not exceeding 10 mg per day of prednisone or its equivalent,&#xD;
             corticosteroids for antiemetic purposes, corticosteroids used as premedication for&#xD;
             hypersensitivity reactions (injected CT scan, taxanes, etc.)&#xD;
&#xD;
          4. Patient participating in another research that may modify the systemic treatment&#xD;
             administered in the framework of the cohort in which she will be included.&#xD;
&#xD;
          5. Pregnant or breastfeeding woman.&#xD;
&#xD;
          6. HIV and / or HBV and / or HCV serology positive.&#xD;
&#xD;
          7. Life expectancy estimated at less than 3 months.&#xD;
&#xD;
          8. Patient's refusal.&#xD;
&#xD;
          9. Person benefiting from a protection system for adults (including tutorship and&#xD;
             curatorship).&#xD;
&#xD;
         10. Inability to undergo medical monitoring of the trial for geographical, social or&#xD;
             psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain LADOIRE, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>centre Georges François Leclerc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain LADOIRE, PU-PH</last_name>
    <phone>03 80 73 75 28</phone>
    <email>sladoire@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie REDERSTORFF</last_name>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando BAZAN</last_name>
      <phone>03 70 63 24 03</phone>
      <email>fbazan@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain LADOIRE, PU-PH</last_name>
      <phone>03 80 73 75 28</phone>
      <email>sladoire@cgfl.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune response</keyword>
  <keyword>blood samples</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

